Recurrent basal cell carcinoma following ablative laser procedures

Jung, Dae Soo; Cho, Hyun-Ho; Ko, Hyun‐Chang; Bae, Yong-Chan; Oh, Chang‐Keun; Kim, Moon-Bum; Kwon, Kyung‐Sool

doi:10.1016/j.jaad.2010.02.040

Cited by 17 publications

(10 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In patients previously treated with ablative lasers, Yung et al. showed that subclinical tumor spread tended to occur in deeper tissue layers rather than at the lateral margins . Regular clinical follow‐up after laser treatment is therefore indispensable.…”

Section: Topical Treatmentmentioning

confidence: 99%

S2k Guidelines for Cutaneous Basal Cell Carcinoma – Part 2: Treatment, Prevention and Follow‐up

Lang

Balermpas

Bauer

et al. 2019

J Deutsche Derma Gesell

125

View full text Add to dashboard Cite

SummaryBasal cell carcinoma (BCC) is the most common malignant tumor among fair‐skinned individuals, and its incidence had been steadily rising in the past decades. In order to maintain the highest quality of patient care possible, the German S2k guidelines were updated following a systematic literature search and with the participation of all professional societies and associations involved in the management of the disease. Part 2 addresses issues such as proper risk stratification, the various therapeutic approaches, and prevention as well as follow‐up of patients with basal cell carcinoma.

show abstract

Section: Topical Treatmentmentioning

confidence: 99%

S2k Guidelines for Cutaneous Basal Cell Carcinoma – Part 2: Treatment, Prevention and Follow‐up

Lang

Balermpas

Bauer

et al. 2019

J Deutsche Derma Gesell

125

View full text Add to dashboard Cite

show abstract

“…According to recent data the recurrence rate after ablative laser therapy varies between 3.7 and 15.5%. [1718]…”

Section: Therapeutic Approaches At Treatment Of Bccmentioning

confidence: 99%

Clinical variants, stages, and management of basal cell carcinoma

Dourmishev

Rusinova²,

Botev

2013

Indian Dermatol Online J

106

View full text Add to dashboard Cite

Basal cell carcinoma (BCC) is the most common paraneoplastic disease among human neoplasms. The tumor affects mainly photoexposed areas, most often in the head and seldom appears on genitalia and perigenital region. BCC progresses slowly and metastases are found in less than 0.5% of the cases; however, a considerable local destruction and mutilation could be observed when treatment is neglected or inadequate. Different variants as nodular, cystic, micronodular, superficial, pigment BCC are described in literature and the differential diagnosis in some cases could be difficult. The staging of BCC is made according to Tumor, Node, Metastasis (TNM) classification and is essential for performing the adequate treatment. Numerous therapeutic methods established for treatment of BCC, having their advantages or disadvantages, do not absolutely dissolve the risk of relapses. The early diagnostics based on the good knowledge and timely organized and adequate treatment is a precondition for better prognosis. Despite the slow progress and numerous therapeutic methods, the basal cell carcinoma should not be underestimated.

show abstract

“…Over the past two decades, laser ablation of benign skin lesions such as nevi or seborrheic keratosis on the face has gained wide popularity in Korea. Accordingly, some patients with BCCs are likely to be treated by laser ablation after being diagnosed with these benign skin tumors17. In this respect, the results of this study may be helpful for the early detection of BCCs in Korea.…”

Section: Discussionmentioning

confidence: 84%

Basal Cell Carcinoma-Mimicking Lesions in Korean Clinical Settings

Kim

Mun

et al. 2014

Ann Dermatol

Self Cite

View full text Add to dashboard Cite

BackgroundBasal cell carcinoma (BCC) is the most common form of skin cancer and possesses various clinical features including translucency, ulceration, pigmentation, telangiectasia, and rolled borders. Accordingly, many cutaneous lesions can mimic BCCs and differential diagnosis is difficult.ObjectiveTo clarify the differences in clinical characteristics between BCCs and BCC-mimicking lesions (BMLs), and to determine which clinical characteristics are helpful for an accurate clinical diagnosis of BCC.MethodsWe performed clinicopathologic analysis of cutaneous lesions that received a clinical diagnosis of BCC. All lesions included in this study showed more than one of the following characteristics of BCCs: translucency, ulceration, flecked pigmentation, black or blue hue, telangiectasia, and rolled borders. We compared six clinical characteristics between the BCC group and the BML group.ResultsAmong 48 lesions in the BML group, there were 15 premalignant or malignant lesions and 33 benign lesions. Various dermatoses mimicking BCC that have not been reported in the dermatological literature were identified, including angiosarcoma, vulvar intraepithelial neoplasm, foreign body granuloma, intravascular papillary endothelial hyperplasia, sarcoidosis, and others. Compared to the BML group, the BCC group had a significantly higher frequency of translucency (76.3% vs. 52.1%, p<0.001), ulceration or erosion (44.2% vs. 27.1%, p=0.022), black or blue hue (40.0% vs. 22.9%, p=0.020), and rolled borders (49.5% vs. 14.6%, p<0.001). Cutaneous lesions with two or less clinical features of BCC were significantly more likely to be BMLs.ConclusionThe results of this study could be helpful for the differential diagnosis of BCCs and BCC-mimicking cutaneous lesions.

show abstract

Recurrent basal cell carcinoma following ablative laser procedures

Cited by 17 publications

References 19 publications

S2k Guidelines for Cutaneous Basal Cell Carcinoma – Part 2: Treatment, Prevention and Follow‐up

S2k Guidelines for Cutaneous Basal Cell Carcinoma – Part 2: Treatment, Prevention and Follow‐up

Clinical variants, stages, and management of basal cell carcinoma

Basal Cell Carcinoma-Mimicking Lesions in Korean Clinical Settings

Contact Info

Product

Resources

About